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Available online 6 March 2016Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K which is an important enzyme for the
degradation of collagen I. Aim of the present work was the head-to-head comparison between the effects of
ODN and alendronate (ALN) on bone mineralization density distribution (BMDD), based on quantitative
backscattered electron imaging in relation to changes in histomorphometric mineralizing surface per bone
surface (MS/BS) in 12–22 years old ovariectomized rhesus monkeys. Trabecular and cortical BMDD derived
parameters from vertebrae and proximal tibiae were compared among vehicle (VEH, n = 8), odanacatib low
dose (ODN-L, n = 8), odanacatib high dose (ODN-H, n = 8), and alendronate (ALN, n = 6) treated animals.
Additionally, data from an intact, non-treated group of animals are shown (INT, n = 8). In trabecular bone
from the vertebra and metaphyseal tibia, the BMDD of the ODN and ALN treatment groups was shifted toward
higher mineralization densities (p b 0.001) consistent with the signiﬁcant reduction of MS/BS (p b 0.05 in
ODN-H and ALN) compared to VEH. Vertebral trabecular CaMean (average degree of mineralization) was signif-
icantly higher in ODN-L (+6.5%), ODN-H (+6.1%), and ALN (+6.7%, all p b 0.001). Tibial osteonal cortical bone
revealed also signiﬁcantly increased CaMean for ODN-L (+1.4%, p b 0.05), ODN-H (+2.2%, p b 0.05), and ALN
(+3.4%, p b 0.001) versus VEH, while primary cortical bone (devoid of secondary osteons) did not show any sig-
niﬁcant differences between the study groups. The percentage of primary bone area in the tibial cross-sections
(on average 45± 12%)was also not signiﬁcantly different between the study groups (p= 0.232). No signiﬁcant
differences in any BMDD parameters of all studied skeletal sites between ODN and ALN treatment were found.
Correlation analysis revealed thatMS/BSwas highly predictive for trabecular BMDD in vertebral bone. The higher
MS/BS, the lowerwas CaMean. Our ﬁndings are consistentwith the inhibition of bone resorption of ODN and ALN
in trabecular and osteonal compartments.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin
K which is an important enzyme for the degradation of collagen I
by osteoclasts (Duong, 2012) and has been developed for its use in
high bone turnover diseases such as postmenopausal osteoporosis
(Reginster et al., 2014). The efﬁcacy of ODN at different formulae and
doses was shown in numerous preclinical animal studies. In
estrogen-deﬁcient rabbits, ODN prevented bone loss (Pennypacker
et al., 2011) and had different effects compared to ALN as shown by
histomorphometry (Jensen et al., 2014). Studies on ovariectomized
rhesus monkeys (Masarachia et al., 2012; Williams et al., 2013) reported
that ODN reduced trabecular bone turnover and increased bone mineralte of Osteology, UKH Meidling,
of).
. This is an open access article underdensity (BMD) in a dose-dependent manner. Furthermore, it increased
femoral corticalwidth due to preservation of endocortical bone formation
rate and increase in periosteal bone apposition in OVX rhesus monkeys
(Cusick et al., 2012; Cabal et al., 2013; Pennypacker et al., 2014).
Phase III trials have conﬁrmed that ODN treatment increased BMD
in lumbar spine and total hip in postmenopausal osteoporotic pa-
tients (Chapurlat, 2015). In particular, increases in cortical thickness,
area and estimates of ﬁnite element analysis-derived strength at radius,
tibia and hip were described after ODN treatment in postmenopausal
osteoporotic women (Brixen et al., 2013; Cheung et al., 2014). Long-
term effects of ODN at 50-mg once-weekly in patients are currently
studied in the phase III Long-Term ODN Fracture Trial (LOFT) (Bone
et al., 2015). Duong et al. recently summarized all ODN trials (Duong
et al., 2015).
Information of bone material quality after ODN treatment is sparse.
Among the bone quality parameters, the degree and heterogeneity of
bone mineralization are important determinants for the intrinsicthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
63B.M. Misof et al. / Bone Reports 5 (2016) 62–69elasticity/stiffness and other mechanical properties of the bone material
(Currey, 2004; Fratzl et al., 2004). In particular, the assessment of poten-
tial treatment effects on bone matrix mineralization is an important
aspect of the general evaluation of treatment-related assessments of
bone quality. In the present study, bone matrix mineralization properties
were investigated at the micron structural level using quantitative back-
scatter electron imaging (qBEI) (Roschger et al., 2008). Employing this
method, the degree of mineralization (the mineral content of the bone
matrix) and its spatial distribution as well as its heterogeneity within
the bone tissue can be determined. Thus, this method allows detec-
tion of the degree of mineralization, independent of bone volume.
In the current prevention mode study, ovariectomized non-human
primates were treated with two doses of odanacatib (ODN) of a new
formulation. We previously reported at oral administration of ODN at
6 and 30mg/kg/day in the conventionalmethocel formulation provided
subclinical exposures (2 and 4 μM-hr0–24) in monkeys (Cusick et al.,
2012). These subclinical ODN doses did not affect bone matrix mineral-
ization signiﬁcantly as reported previously (Fratzl-Zelman et al., 2013).
Trends of dose-dependent shifts toward higher bonematrixmineraliza-
tion with ODN could be observed, and the effect was more pronounced
at sites with higher remodeling rates (Fratzl-Zelman et al., 2013). To
investigate the bone safety proﬁle of ODN, a second study in rhesus
monkeys was carried out with doses higher than the clinical exposure
of ODN (6–7 μM-hr0–24) as estimated from the 50-mg once-weekly
dose in humans (Stoch et al., 2009). Twodoses of ODNwere administered
orally daily to OVX-rhesus monkeys for 20-months using a novel formu-
lation that achieved steady state drug exposures at ~1.8 (ODN-L) and
~7.8-fold (ODN-H) of the clinical exposure (Williams et al., 2013). These
were compared to alendronate (ALN) subcutaneous dose selected to pro-
duce a plasma concentration approximate to the 70-mg oral once-weekly
dose in human (Thompson et al., 1992). The aim of the present studywas
to measure the BMDD at trabecular and cortical sites after 20 months of
treatment with two different doses of ODN treated and to compare the
results head to head with alendronate (ALN) and vehicle (VEH) treat-
ment. For additional information, BMDDof untreated, not ovariectomized
animals (INT) was analyzed. Furthermore, mineralizing bone surface per
bone surface, a primary histomorphometric index of bone formation, was
assessed for supporting of the interpretation of the bone matrix mineral-
ization outcomes.
2. Material and methods
2.1. Study design
All procedures were approved by the Institutional Animal Care and
Use Committee of Merck Research Laboratories. Sixty-four female
rhesusmonkeys (Macacamulatta 12–22 years of age) were randomized
into four groups as previously described (Williams et al., 2013). Following
bilateral OVX, the groups received the following treatments: (i) Vehicle
(VEH) containing the enhanced formulation hydroxypropyl methyl
cellulose acetate succinate (HPMC-AS) polymer; (ii) ODN at 2 mg/kg,
(ODN-L, p.o., q.d.); (iii) ODN at 4 mg/kg (ODN-H, p.o., q.d.); (iv) ALN
at 30 μg/kg/week (15 μg/kg twice weekly, s.c.). Drug treatment was
initiated in prevention mode, approximately 10-days post-surgery.
ALN at 15 μg/kg twice weekly, s.c. was approximately the i.v. dose of
50 μg/kg every two weeks, which was previously demonstrated to
fully protect estrogen-deﬁciency induced bone loss in OVX baboons
(Thompson et al., 1992). Compared to the daily clinical exposure of
6–7 μM·hr0–24 estimated from the ODN 50-mg once-weekly dose, the
24 h plasma exposure (AUC0–24) for the ODN-L (2 mg/kg/d) dosed in
HPMC-AS formulation was ~12 μM·hr0–24 in monkey. ODN-H group
was initially dosed with ODN 8 mg/kg/d, progressively resulting in a
drug concentration of 142 μM·hr0–24; hence, this dose groupwas subse-
quently reduced to 4 mg/kg/d after 5.5 months, to maintain plasma
exposure of ODN at 51 μM·hr0–24 for the rest of the study duration.
For additional information, samples of a separate group of aged andbody weight matched intact (INT) animals (outside the study groups)
whichwere not ovariectomized and remained untreatedwere analyzed
and outcomes are shown.
The study groups were maintained on a high protein diet (19.8%)
containing 1.17% Ca, 0.7% P, 8 IU/g vitamin D3 diet (Harlan Teklad 8773
NIB primate diet ~200 g/d). To obtain dynamic histomorphometric
measurements of the bone forming surfaces, double ﬂuorochrome labels
with a 15-day or 14-day interval were administered at two different time
points during the study: calcein (CAL, 12 mg/kg, s.c.) at month 12, and
tetracycline (TCY, 40 mg/kg, i.v.) at month 20, respectively.
2.2. Bone samples
A total of 30 samples (n = 8 VEH, n = 8 ODN-L, n = 8 ODN-H, and
n= 6 ALN) were randomly selected from the four treatment groups for
material level measurements of BMDDusing qBEI. Additionally samples
fromn=8 INTweremeasured. Lumbar vertebrae 6 (LV6)were dissect-
ed at necropsy and halved frontally after gentle removal of soft tissue;
the ventral plane was retained for analysis. Tibiae were disarticulated
from femora and adherent tissues gently removed. Using a band saw
(Exakt band system 300/CP; Exakt Advanced Technologies, GmbH
Norderstedt, Germany), the tibiaewere cut into two separate sections, de-
ﬁningmetaphyseal and cortical sections. Ametaphyseal section was ob-
tained by transversally cutting 2 cm of the proximal condyle to
expose the trabecular bone. A second frontal cut was then made
through the proximal condyle to deﬁne themetaphyseal tibia. The di-
aphyseal cortexwas deﬁned by a 1-cm transversal section of the central
tibiae, approximately 5–6 cm from the distal end of the tibia. Samples
were stored in 70% ethanol. Investigators were blinded to the allocation
of the bone samples in treatment groups.
2.3. Histomorphometry of trabecular and cortical bones
Longitudinal sections (6-μm) were cut on a Leica SM 2500S sledge
microtome (Leica Biosystems, Heidelberg, Germany) and mounted on
glass slides (Fisher Scientiﬁc, Pittsburgh, PA, USA). Coverslips were
applied using Eukitt's mounting media (EMS, Ft. Washington, PA,
USA). For cortical bone histomorphometry of the central tibia, bone
specimens were processed as described above, followed by embedding
in 90% methyl methacrylate/10% dibutyl phthalate. Cross sections of
120-μm thickness were collected.
For the lumbar vertebrae (LV6), measurements were made in a
3 × 4-mm area of interest (ROI) of the 1/3 caudal aspect of the plane
of section placed about 1 mm from the end plate and centered between
the dorsal and ventral sides. All histomorphometric measurements for
bone specimens were performed on a light/epiﬂuorescent microscope,
Nikon Eclipse 80i (Nikon Instruments, Melville, NY, USA) equipped
with an Optonics DEI-750 CE (Tuttlingen, Germany) video camera
interfaced to an image analysis system (Bioquant R&M Biometrics,
Nashville, TN, USA). All measurements and calculations of dynamic
histomorphometry for trabecular and cortical bones followed a standard
method as previously described (Dempster et al., 2013).
Dynamic indices were measured in all samples except in four which
had to be excluded for measurement of trabecular indices at 12 months
of treatment due to wrong labeling schedule. Mineralizing surface
(MS/BS, %) was calculated as double plus half the single-labeled surface
divided by total bone surface. Thus, in cases where no double labels
were found, MS/BS represents the half of the single labeled surface
per bone surface. CAL and TCY labeling were measured at trabecular
(Tb) surfaces of LV6 and proximal tibiae sites, and at periosteal (Ps)
and endocortical (Ec) surfaces of the central tibiae.
2.4. Quantitative backscatter electron imaging (qBEI)
Samples for qBEI measurements were prepared from the same bone
specimens used for histomorphometric analysis. Sample blocks were
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Buff, IL, USA). Sectioned bone surfaces were sequentially grinded with
sand paper with increasing grid number followed by polishing with
diamond grains (size down to 1.0 μm) on hard polishing clothes by a
precision polishing device (PM5 Logitech, Glasgow, Scotland). Finally
the sample surface was carbon coated by vacuum evaporation (Agar
SEM Carbon Coater, Stansted, UK).
The qBEI technique is well established and validated and the details
of the method have been published elsewhere (Roschger et al., 2008).
Brieﬂy, qBEI makes use of the fact that the intensity of electrons
backscattered from a depth of 1.5 μm from the surface-layer of a sec-
tioned bone area is proportional to the weight concentration of mineral
(hydroxyapatite/calcium) in bone. A digital electron microscope (DSM
962, Zeiss, Oberkochen, Germany) equippedwith a four quadrant semi-
conductor backscattered electron (BE) detector was used. The BE-signal
(gray scale) was calibrated using the “atomic number contrast” between
carbon (C, atomic number 6) and aluminum (Al, atomic number 13) as
reference materials. Carbon was set to gray level index 25 and Al to 225.
This allows a scaling also into weight % (wt%) Ca, whereby, osteoid
(atomic number ~ 6) has 0 wt% Ca and pure hydroxyapatite (atomic
number 14.06) has 39.86 wt% Ca according to its composition. Thus,Fig. 1. Examples of qBEI overview images of the bone sections analyzed. The regions of interest a
with sixROIs: 2 central (C andD), and 4 zones closer to the vertebral endplates (A, B, E, F). B) Lon
by 6 ROIs. C) Transversal section of tibialmidshaft cortexwith four ROIs: A and B in the sector of
long axis of cross section. These ROIs were divided into primary (p) and osteonal (o) bone regone gray level step corresponds to 0.17 wt% Ca as a consequence of
this calibration protocol.
Digital calibrated BE-images were acquired with a 50× nominal
magniﬁcation (resolution 4 μm/pixel) from the sectioned bone areas
of selected ROIs (Fig. 1). From these images, gray-level histograms
(frequency distributions) were generated indicating the percentage of
mineralized bone area (y-axis) corresponding to the number of pixels
with a certain gray level (x axis). Following calibration, the BE-image
gray-level distribution can be interpreted as awt% Ca bonemineralization
density distribution (BMDD) for bone tissue. Five BMDDparameterswere
measured to characterize the BMDD for statistical analysis (Roschger
et al., 2003):
1) CaMean is the weighted average Ca concentration of the mineralized
tissue area, obtained from the integrated area under the BMDD curve.
2) CaPeak is the peak position of the BMDD histogram showing the
most frequently occurring wt% Ca of the measured areas.
3) CaWidth is thewidth at half-maximumof the BMDDhistogrampeak
indicating the heterogeneity of mineralization.
4) CaLow is the fraction of lowly mineralized tissue area (below
17.68 wt% Ca which is the 5th percentile of trabecular bone from are indicated bywhite boxes (dashed lines). A)Half vertebral frontal section (ventral plane)
gitudinal front section of proximalmetaphyseal boneof tibia. Central regionwere analyzed
theminor axis of the ellipsoidal cortical cross sectional area and C andD in the sector of the
ions for separate analysis.
Table 1
BMDD results from trabecular and cortical sites of all treatment groups.
Treatment groups
INTa VEH ODN–L ODN–H ALN p–Value
V
er
te
br
al
 t
ra
be
cu
la
r
CaMean
[wt%]
21.09
(0.66)
20.95 
(0.51)
22.31***
(0.38)
22.22 ***
(0.82)
22.36***
(0.68)
<0.001
CaPeak
[wt%]
22.12
(0.72)
21.90 
(0.49)
23.07 ***
(0.42)
23.03***
(0.75)
23.08***
(0.71)
0.001
CaWidth
[∆wt%]
4.01
(0.44)
4.29 
(0.69)
3.34 ***
(0.39)
3.62 **
(0.29)
3.26***
(0.14)
<0.001
CaLow
[%]
9.01
(2.91)
9.34
(2.93)
5.66***
(0.87)
5.92***
(1.03)
5.01***
(0.37)
<0.001
CaHigh
[%]
3.11
(2.17)
2.63
(1.94)
8.10
(3.86)
9.85
(7.53)
8.69
(6.57)
n.s.
(0.058)
se
al
 t
ra
be
cu
la
r CaMean
[wt%]
22.09
(0.50)
21.30 
(0.82)
22.15 **
(0.43)
22.45 ***
(0.34)
22.46***
(0.24)
<0.001
CaPeak
[wt%]
23.01
(0.57)
22.20 
(0.65)
22.88 **
(0.43)
23.24 ***
(0.22)
23.02**
(0.34)
<0.001
CaWidth
[∆wt%]
3.44
(0.27)
3.60 
(0.37)
3.18 **
(0.26)
3.21 **
(0.21)
3.18**
(0.21)
0.013
65B.M. Misof et al. / Bone Reports 5 (2016) 62–69human adult reference BMDD data base (Roschger et al., 2003) and
indicates the percentage of primary mineralized areas in human
bone).
5) CaHigh indicates the fraction of area of highly mineralized bone
tissue (N25.30wt% calciumwhich is the 95th percentile of trabec-
ular bone from a human adult reference BMDD data base
(Roschger et al., 2003).
2.5. Correlation of BMDD parameters with histomorphometric dynamic
indices of bone turnover
For the correlation analyses, data from all animal groups (INT, VEH,
ODN-L, ODN-H, ALN) were considered. For correlation in vertebral
trabecular bone, 5 samples had to be omitted (n = 2 INT, n = 2 ODN-L,
n = 1 ODN-H) due to the occurrence of local/focal abnormal features
typical for hyperostosis; note that the local abnormalities are not speciﬁc
to any group. Hyperostosis is a form of degradation, relatively commonly
found in vertebral bone from aged rhesus monkeys (Swezey et al., 1991)
and characterized by local increased bone resorption and extensive new
bone apposition on the surface of the pre-existing bone motifs. The latter
affects local bone matrix mineralization at the site of hyperostosis. As
these focal changes in bone matrix mineralization were not representa-
tive for the entire sample, these areas of abnormal bone formation were
carefully excluded for BMDD in the mentioned n = 5 samples (i.e. none
of the ROIs of BMDD measurement as indicated in Fig. 1 contained areas
of hyperostosis). Moreover, these 5 samples mentioned were excluded
from Tb.MS/BS comparison among the study groups (Table 2) and the
analysis of correlation with BMDD outcomes (Table 3, Fig. 4).
2.6. Assessment of relative percentage of primary vs. osteonal bone area in
tibial cross-sections
Stitching of the digital backscatter electron images acquired at a
nominal magniﬁcation of 12× (pixel resolution 9 μm/pixel) was used
for receiving overview images of the entire area of the tibial cross-
sections. In these images osteonal areas (areas of secondary osteons,
osteonal B·Ar) and primary bone areas (devoid of secondary osteons,
prim. B·Ar) were identiﬁed throughout by the same experienced
observer (PM). An example of a cross-sectional area with indicated
osteonal and primary bone area is shown in Fig. 1C. The number of
pixels for osteonal and primary bone were used for the calculation
of percentage of primary bone as follows:
%prim:B:Ar ¼ 100 prim:B:Ar= prim:B:Arþ osteonal B:Arð Þ½ Fig. 2. Representative examples of treatment effects on vertebral cancellous bone: a
representative BMDD per study group (INT, VEH, ODN-L, ODN-H and ALN).2.7. Statistical analysis
All results are shown as the mean ± standard deviation (SD) or
median (25th, 75th percentiles) for normally or non-normally
distributed data, respectively. Differences among the four study
groups were analyzed by one way analysis of variance (ANOVA) or
non-parametric Kruskal-Wallis ANOVA on ranks (latter for non-
normally distributed data), followed by Fisher LSD post-hoc or Dunn's
multiple comparison. Correlation analyses are based on Spearman rank
order correlation or Pearson Product moment correlation. Statistical sig-
niﬁcance was considered at p b 0.05.
3. Results
Fig. 1 shows the regions of interest (ROIs) for BMDDmeasurements
at four different skeletal sites (vertebral trabecular bone, tibial
metaphyseal trabecular bone, osteonal tibial midshaft bone, and primary
tibial midshaft bone) of animals from INT (not included in the original
randomization) and study groups VEH, ODN-L, ODN-H, and ALN. One
example of tibial cortical bone is shown to demonstrate the separation
of osteonal and primary tibial bone (Fig. 1C).
(A) Treament effects in trabecular BMDDof L6 vertebra and proximal
tibia
Treatment with ODN-L, ODN-H or ALN signiﬁcantly affected the
BMDD of trabecular bone. One representative example of trabecular
vertebral BMDD of each treatment group (VEH, ODN-L, ODN-H, ALN)
is shown in Fig. 2. For instance the BMDD of ODN-L was clearly shifted
to higher mineralization densities with respect to VEH, which was alsoM
et
ap
hy CaLow
[%]
5.77
(1.05)
7.48 
(3.01)
5.45 *
(0.91)
5.59 
(1.97)
4.03**
(0.28)
0.022
CaHigh
[%]
6.16
(4.52)
2.50
(1.92)
5.53*#
(3.53)
8.18***
(1.85)
5.96*
(2.42)
0.002
O
st
eo
na
l c
or
ti
ca
l
CaMean
[wt%]
24.56
(0.53)
24.05
(0.51)
24.39*
(0.33)
24.58*
(0.36)
24.89***
(0.27)
0.004
CaPeak
[wt%]
25.24
(0.45)
25.04
(0.56)
25.09
(0.27)
25.28
(0.45)
25.45
(0.37)
n.s.
CaWidth
[∆wt%]
3.27
(0.36)
3.64
(0.70)
3.16
(0.37)
3.12
(0.31)
3.44
0.37
n.s.
CaLow
[%]
2.56
(0.59)
3.34
(0.69)
2.75*
(0.44)
2.99
(0.45)
2.45**
(0.26)
0.018
CaHigh
[%]
45.97
(12.0)
37.95
(11.63)
41.17
(8.99)
47.56
(12.62)
52.69
(8.54)
n.s.
(0.071)
Pr
im
ar
y 
co
rt
ic
al
CaMean
[wt%]
25.62
(0.43)
25.36
(0.54)
25.27
(0.50)
25.19
(0.61)
25.70
(0.41)
n.s.
CaPeak
[wt%]
26.00
(0.51)
25.76
(0.39)
25.82
(0.51)
25.74
(0.60)
26.17
(0.44)
n.s.
CaWidth
[∆wt%]
2.60
(2.43; 2.60)
2.25
(2.25; 2.43)
2.43
(2.34; 2.60)
2.25
(2.25; 2.51)
2.69
(2.43; 2.77)
n.s.
CaLow
[%]
1.97
(0.24)
2.08
(0.61)
2.09
(0.44)
2.56
(0.49)
2.19
(0.25)
n.s.
CaHigh
[%]
72.85
(11.05)
67.99
(13.44)
64.88
(11.99)
64.87
(19.40)
74.95
(10.34)
n.s.
Data are mean (SD) or median (25th; 75th percentiles). p–Value is based on ANOVA or
non–parametric Kruskal–Wallis comparison between treatment groups. 
aNo statistical comparison to INT was performed.
***p ≤ 0.001, **p < 0.01, *p < 0.05 vs. VEH based on post–hoc Fischer LSD method
#p < 0.05 vs. ODN–H based on post–hoc Fischer LSD method
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changes of BMDD curves could be observed also for ODN-H and ALN
(Fig. 2).
Statistical comparison of the four treatment groups revealed signiﬁ-
cant differences in all trabecular BMDDderived parameters at both sites,
vertebra and tibia. Corresponding ANOVA or ANOVA on ranks and post-
hoc tests are summarized in Table 1. Percent differences of all trabecular
BMDD parameters in the study groups to VEHmean are shown in Fig. 3.
In particular, CaMean and CaPeak of trabecular bone in vertebrae and
proximal tibia bone were signiﬁcantly higher in ODN-L (CaMean:
+6.5%, p b 0.001 and +4.0%, p b 0.01), ODN-H (CaMean: +6.1%,
p b 0.001 and +5.4%, p b 0.001), and ALN treated groups (CaMean:
+6.7%, p b 0.001 and+5.4%, p b 0.001 for trabecular bone in vertebrae
and tibial metaphysis, respectively) compared to VEH, while CaWidth
and CaLow were signiﬁcantly reduced in ODN-L, ODN-H, and ALN
treated groups compared to VEH (Table 1).
No signiﬁcant differences between theBMDDparameters among the
groups treated with the bone resorption inhibitors (ODN-L vs. ODN-H
vs. ALN), could be detected (all post-hoc tests N0.05)with the exception
of metaphyseal tibial CaHigh which was higher in ODN-H compared to
ODN-L (p b 0.05).
(B) Treatment effects in cortical BMDD in central tibia
Comparison of the four treatment groups revealed signiﬁcant
differences in BMDD from osteonal and no signiﬁcant differences
from those of primary (devoid of secondary osteons) cortical bone
of the tibia (corresponding ANOVA or ANOVA on ranks and post-hocFig. 3. Effects of 20months treatment on BMDD of vertebral trabecular bone. The differences to
ﬁne shaded), and ALN (black). Bars indicate mean ± SD. * p b 0.05,** p b 0.01, *** p b 0.001 vetests are summarized in Table 1). Tibial osteonal CaMeanwas increased
for ODN-L (+1.4%, p b 0.05), ODN-H (+2.2%, p b 0.05) and ALN treated
animals (+3.4%, p b 0.001) while tibial osteonal CaLow was decreased
for ODN-L (−17.7%, p b 0.05) and ALN (−26.6%, p b 0.01) compared to
VEH treated.
Mean and standard deviation of percentage of primary bone area
(%prim. B.Ar) was 41 ± 14% for INT, 40 ± 11% for VEH, 42 ± 4% for
ODN-L, 45±13% for ODN-H, and 51±13% for ALN. ANOVA comparison
between the treatment groups (comparing VEH, ODN-L, ODN-H, and
ALN) showed no signiﬁcant differences (p = 0.232) in % prim. B.Ar.
(C) Treatment effects on mineralizing surface per bone surface and
correlation with BMDD parameters
Average levels (median and interquartile range) of trabecular (Tb.MS/
BS), periosteal (Ps.MS/BS), and endocortical mineralizing surface per
bone surface (Ec.MS/BS) from all study groups and INT animals are
shown in Table 2 (INT data were not included for statistical analysis).
After 12 and 20 months of treatment, ODN-H and ALN reduced Tb.MS/
BS versus VEH. No signiﬁcant differences among the study groups were
observed for Ps.MS/BS or Ec.MS/BS. These parameters, however, revealed
a large inter-individual variation within the groups. A high percentage of
samples were lacking double labels at both 12 months and 20 months of
treatment. Details on the number of samples with double labels are
shown in Table 2.
Regression analyses between Tb.MS/BS and BMDD variables were
performed for all groups (INT, VEH, ODN-L, ODN-H, ALN) or only with
the ovariectomized study groups (Table 3). Highly signiﬁcantVEHmean are shown for INT (gray), ODN-L (light gray, coarse shaded), ODN-H (light gray,
rsus VEH (ANOVA post-hoc tests from Table 1).
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tion rate at 12 months treatment) with BMDD parameters were found
in vertebral trabecular bone (Table 3). Similarly, correlations with
Tb.MS/BS based on tetracycline labels (reﬂecting bone formation rate
at 20months treatment) could be observed (Table 3). Vertebral trabec-
ular CaMean plotted versus Tb.MS/BS at 12 months and at 20 months is
shown in Fig. 4 (statistical outcomeswith andwithout the INT group are
shown).
Regression analysis between central cortical tibial Ps.MS/BS or
Ec.MS/BS with BMDD outcomes including all animal groups revealed
no signiﬁcant relationshipwith the exception of a signiﬁcant correlation
between primary cortical bone CaLow and Ec.MS/BS based on calcein
labels (R = 0.39, p = 0.02). This correlation remained statistically
signiﬁcant if the INT group was omitted from analysis (R = 0.37, p =
0.04). Moreover, no signiﬁcant correlations between primary bone areas
(%prim. B.Ar) and bone formation at the tibiae (Ps.MS/BS, Ec.MS/BS)
could be observed.
4. Discussion
We have studied the effects of 20 months treatment with ODN-L or
ODN-Hhead to head comparison to ALNon the bonematrixmineraliza-
tion in OVX adult rhesus monkeys. For this study, bone samples were
obtained from animals treated with two doses of ODN at ~1.8 fold
(ODN-L) and ~7.8 fold (ODN-H) clinical exposure estimated from
ODN 50-mg once-weekly and a dose of ALN equivalent to the 70-mg
once-week (Williams et al., 2013). We observed a signiﬁcant shift of
the BMDD toward higher mineralization densities in trabecular and
osteonal compartments with ODN at both doses and ALN. In contrast,
primary bone of the tibiae (devoid of secondary osteons) did not reveal
this shift toward higher bone matrix mineralization. CorrelationTable 2
Histomorphometric mineralizing surface per bone surface (MS/BS) in OVX-rhesus monkeys.
Group Intacta
Study groups (O
Veh
Vertebral trabecular bone at 12 months of treatment
# samplesb 6 8
# samples with DL 6 7
# samples with any label 6 8
Tb.MS/BS (%) 3.80 (2.30; 4.90) 8.90 (4.05; 11.70
Vertebral trabecular bone at 20 months of treatment
# samplesc 6 8
# samples with DL 6 7
# samples with any label 6 7
Tb.MS/BS (%) 4.92 (2.72; 10.71) 2.95 (1.60; 5.20)
Tibial cortical bone at 12 months of treatment
# samples 8 8
# samples with DL at Ps sites 2 5
# samples with any label at Ps sites 2 6
Ps.MS/BS 0.00 (0.00; 0.85) 5.17 (0.50; 12.96
# samples with DL at Ec sites 6 4
# samples with any label at Ec sites 7 7
Ec.MS/BS 8.72 (0.88; 17.31) 1.52 (0.71; 11.48
Tibial cortical bone at 20 months of treatment
# samples 8 8
# samples with DL at Ps sites 3 3
# samples with any label at Ps sites 5 5
Ps.MS/BS 0.35 (0.00; 4.60) 0.43 (0.00; 5.64)
# samples with DL at Ec sites 6 3
# samples with any label at Ec sites 8 6
Ec.MS/BS 5.85 (2.50; 8.60) 1.34 (0.15; 2.58)
Data are median (25th; 75th percentiles).
Tb.MS/BS= trabecularmineralizing surface per bone surface, Ps.MS/BS=periostealmineralizin
⁎ p b 0.05 vs. VEH by Dunn's pairwise comparison (following Kruskal-Wallis comparison of
a Not included in the statistical analysis.
b 9 samples had to be excluded (4 due to wrong labeling schedule and 5 due to hyperosteos
c 5 samples had to be excluded due to hyperosteosis.analyses of trabecular bone Tb.MS/BS versus BMDD parameters (both
derived from vertebrae) revealed that treatment-related reductions in
Tb.MS/BS were correlated with the increases in the degree of minerali-
zation and the decreases in heterogeneity of mineralization.
The observed BMDD outcomes in ODN-L, ODN-H, ALN compared to
VEH after 20 months of treatment were completely consistent with
the antiresorptive action of a bisphosphonate, as previously reported
on treatment with ALN or other antiresorptive agents in bone from
postmenopausal osteoporotic women (Roschger et al., 2014). Higher
CaMean, CaPeak and CaHigh are indicative for increased average tissue
age in treated bone. This is due to a prolonged period of secondary
mineralization in the bone structural units (BSUs). Simultaneously,
CaLow, the fraction of lowly mineralized bone areas was signiﬁcantly
decreased, as less new BSUs were formed during treatment. Further,
CaWidth, the heterogeneity of the matrix mineralization was reduced,
which represents a typical transient effect on the BMDD, when the
bone turnover rate has dropped to a lower level (Ruffoni et al., 2008;
Roschger et al., 2014). Our previous studywithODNdosed at subclinical
exposures did not show statistically signiﬁcant changes in BMDD (Fratzl-
Zelman et al., 2013). In the present work, ODN at doses higher than
clinical exposures signiﬁcantly increased secondary mineralization as
compared to VEH controls. The dependency of the BMDD outcomes on
bone turnover is reﬂected by the signiﬁcant correlations of mineralizing
surface with BMDD parameters obtained from vertebral trabecular bone.
It is important to note this study was conducted in prevention when
drug dosing started 10 days post-OVX (Williams et al., 2013), therefore
treatment-related actions on bone occurred during the high remodeling
status in skeletal mature monkeys at newly estrogen deﬁcient condi-
tion. By comparing ODN to ALN, the effect on trabecular BMDD is very
similar for both drugs, although their mechanisms of reduction of
bone turnover are very different (Duong, 2012; Reginster et al., 2014).VX)
ODN-L 2 mg/kg/d ODN-H 4 mg/kg/d ALN 30 μg/kg/wk
4 6 5
3 1 1
4 6 3
) 1.60 (0.75; 2.55) 0.30 (0.20; 0.30)⁎ 0.50 (0.00; 1.08)⁎
6 7 6
3 2 3
3 2 3
0.02 (0.00; 0.38) 0.00 (0.00; 0.02)⁎ 0.03 (0.00; 0.09)
8 8 6
7 7 5
8 7 5
) 6.25 (2.49; 39.24) 3.63 (2.94; 8.22) 3.58 (1.48; 11.75)
3 5 4
8 7 4
) 2.52 (0.35; 10.73) 6.46 (1.49; 20.54) 8.22 (0.00; 13.73)
8 8 6
7 5 0
7 7 3
9.96 (0.83; 27.66) 0.87 (0.46; 8.18) 0.31 (0.00; 0.63)
3 5 1
6 5 4
0.58 (0.16; 6.36) 3.07 (0.00; 6.94) 0.53 (0.00; 1.91)
g surface per bone surface, Ec.MS/BS=endocorticalmineralizing surface per bone surface.
median values p b 0.05).
is).
Table 3
Pearson product moment correlation analysis of trabecular mineralizing surface per bone surface (MS/BS) versus BMDD parameters obtained from vertebral trabecular compartments.
12 months labeling 20 months labeling
L6-vertebra Tb.MS/BS (n = 29)a Tb.MS/BS (n = 23)b Tb. MS/BS (n = 33)a Tb. MS/BS (n = 27)b
CaMean trabecular R =−0.68, p b 0.001 R =−0.61, p = 0.002 R =−0.43, p = 0.01 R =−0.65, p b 0.001
CaPeak trabecular R =−0.58, p = 0.001 R =−0.54, p = 0.008 R =−0.35, p = 0.046 R =−0.57, p = 0.002
CaWidth trabecular R = 0.52 p = 0.004 R = 0.54, p = 0.007 R = 0.48, p = 0.005 R = 0.59, p = 0.001
CaLow trabecular R = 0.70, p b 0.001 R = 0.67, p b 0.001 R = 0.60, p b 0.001 R = 0.84, p b 0.001
CaHigh trabecular R =−0.55, p = 0.002 R =−0.42, p = 0.047 R =−0.35, p = 0.048 R =−0.40, p = 0.037
a Correlations including samples from all groups (INT, VEH, ODN-L, ODN-H, ALN).
b Correlations within OVX-study groups (VEH, ODN-L, ODN-H, ALN).
Fig. 4. Correlation of average calcium concentration of vertebral trabecular bone
(Tb·CaMean) versus mineralizing surface per bone surface (Tb.MS/BS) ((a) based on
calcein (CAL) labels, (b) based on tetracycline (TCY) labels)) measured in the same
bone compartment. Correlation outcomes (Spearman rank order correlation
coefﬁcient R and corresponding p-value) for all animal groups (INT white, VEH
light gray, ODN-L dark gray circle, ODN-H dark gray triangle, and ALN black) and
for those without INT are shown.
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Tb·BMDD appeared to reach a saturation level after 20-months of treat-
ment. There were no differences among the ODN treatment groups that
could be detected for any Tb·BMDD parameter at the four measured
sites with the exception of lower metaphyseal trabecular CaHigh in
the ODN lower compared to ODN higher dose group. The similarity of
the Tb·BMDD effects in ODN at both doses and ALN groups might be
due to the fact that bone turnover is highly reduced in trabecular and
osteonal compartments, consistent with the Tb.MS/BS levels near zero
after 20 months of treatment in both ODN and ALN groups. Strong
treatment-related reductions of Tb.MS/BS, particularly in the ODN-L
(~1.8-fold clinical exposure) and ALN groups (equivalent to clinical
exposure), were evident. The observed reduction in Tb.MS/BS is
consistent with the changes in bone turnover markers at 18 months of
treatment reported for the same monkeys (Williams et al., 2013).
Urinary amino-terminal telopeptides (uNTx) and serum N-propeptide
of type 1 collagen (sP1NP) decreased by about −80% and −50%,
respectively in ODN-L and by −80% (for both markers) in the ALN
group (Williams et al., 2013) compared to VEH.
Tibial diaphyseal central cortical bone of these skeletally mature
rhesus monkeys is highly heterogeneous, consisting of compact, highly
mineralized, primary bone (devoid of secondary osteons), which is co-
existing with secondary osteonal bone. Osteonal bone represents bone
areas with intracortical remodeling. Assessment of the percentages of
primary or osteonal bone areas in the tibial diaphyseal cross-sections
showed that neither parameter was changed by treatment, suggesting
that ODN or ALN treatment did not change the relative amount of area/
volume of intracortical remodeling in the tibial shaft of the monkeys.
Given our selection criterion for primary bone (devoid of secondary
lower mineralized osteons), our BMDD ﬁndings revealed that the
average degree of mineralization (CaMean, Table 2) is numerically
higher than that in osteonal bone in all groups, which is consistent
with a higher average tissue age in primary bone independent of
treatment. Moreover, in osteonal bone, the shift toward higher bone
mineralization densities induced by ODN or ALN treatment similar to
that in trabecular compartments was observed. This is consistent with
the treatment-related inhibition of bone resorption effect on intracortical
bone remodeling as previously reported previously in femoral shaft of the
OVX-rhesus monkeys (Cusick et al., 2012). The lack of treatment effects
on the BMDD in primary cortical bone suggests low bone turnover/
formation activity at this site. In general, signiﬁcant periosteal bone
formation would have been expected to have an impact on the BMDD,
i.e. to decrease the averagemineralization densities due to the presence
of younger bonematrix. Periosteal and endocortical MS/BSmeasured in
cortical bone of the tibia revealed a large variation between the animals
within each group, pointing toward a high intra-individual site-speciﬁc
variation in bone modelling. Further, one might speculate that the
observation of unchanged primary cortical BMDD does not necessarily
exclude the possibility of periosteal bone formation as mineralization
of newly formed bone areas might occur faster at periosteal sites
(Wergedal and Baylink, 1974) and too rapidly for an impact on the
BMDD. However, dynamic histomorphometry demonstrated there
was no treatment related changes detected in periosteal bone formation
69B.M. Misof et al. / Bone Reports 5 (2016) 62–69of the tibia in the ODN groups or ALN. This ﬁnding seems to limit to the
tibial diaphysis, since signiﬁcant periosteal bone formation was pre-
viously reported in ODN-treated femoral sites, including femoral
neck, proximal femur and central femur in OVX-rhesus monkeys
(Cusick et al., 2012).
In summary, ODN dosed in prevention mode at supraclinical expo-
sures increased the degree and reduced the heterogeneity of bonematrix
mineralization in trabecular and intra-cortical (osteonal) compartments.
The similarity of the BMDD effects at both ODN doses indicates that the
maximum effect of this drug on BMDD is already achieved at the lower
(~ 1.8 fold clinical exposure) dose after 20-months of treatment. The over-
all treatment-related effects on BMDD in the spine and tibia were similar
to those of ALN and are in line with the effect of ODN on blocking bone
resorption.
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